Trials / Completed
CompletedNCT01951846
To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours
An Open Label Dose Escalation Study of BIBF 1120 Administered Orally for Four Weeks in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study was to determine the maximum tolerated dose (MTD) of BIBF 1120 in patients with solid tumours by the monitoring of drug-related adverse events. Secondary objectives were the evaluation of safety, efficacy, pharmacokinetics, and pharmacodynamics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIBF 1120 |
Timeline
- Start date
- 2002-11-01
- Primary completion
- 2004-11-01
- First posted
- 2013-09-27
- Last updated
- 2013-09-27
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01951846. Inclusion in this directory is not an endorsement.